肾移植受者前列腺癌的机器人根治性前列腺切除术:多中心系列结果
该回顾性多中心系列纳入41例肾移植受者,描述经腹腔机器人辅助根治性前列腺切除术技术并报告围手术期、肿瘤学与功能结局。作者认为该术式安全可行,围手术期、肿瘤学与功能结局与非移植人群相当,但需进一步研究确认。
要点
- 41例肾移植受者行机器人辅助根治性前列腺切除术,无术中并发症,1例Clavien 3a级并发症。
- 中位随访42个月,4例生化复发,无转移记录,2例死于非前列腺癌原因。
- 术前尿控者术后尿控保留86.1%,术前勃起功能者勃起保留64.7%(P=0.0633)。
核心结论
- 作者认为肾移植受者行机器人辅助根治性前列腺切除术安全可行,围手术期、肿瘤学与功能结局与非移植人群相当,移植物损伤未见报告,需进一步研究确认。
研究设计与样本
- 回顾性多中心系列,纳入四家转诊中心的41例肾移植受者,行经腹腔机器人辅助根治性前列腺切除术,部分患者行盆腔淋巴结清扫。
主要发现
- 中位年龄60岁(IQR 57-64),中位ASA评分2分(IQR 2-3),中位术前肾功能45 ml/min(IQR 30-62),中位PSA 6.5 ng/ml(IQR 5.2-10.2),4例(9.8%)活检Gleason评分>7。
- 70.7%的患者未行淋巴结清扫;中位手术时间201分钟(IQR 170-250),中位住院时间4天(IQR 2-6),中位导尿时间10天(IQR 7-13)。
- 最终病理示11例精囊外侵犯、7例切缘阳性;中位随访42个月(IQR 24-65),4例生化复发(含1例局部前列腺癌持续存在和1例局部复发),无转移记录,2例死于非前列腺癌原因。
- 术前尿控者术后尿控保留86.1%,术前勃起功能者勃起保留64.7%(P=0.0633);肾功能保持不变(P=0.08)。
- 无术中并发症,记录1例重大并发症(Clavien 3a级)。
临床怎么用
- 作者认为肾移植受者行机器人辅助根治性前列腺切除术安全可行,围手术期、肿瘤学与功能结局与非移植人群相当,移植物损伤未见报告,需进一步研究确认。
局限性
- 原文为回顾性多中心系列,样本量41例,作者指出需进一步研究确认其发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite an expected increase in prostate cancer (PCa) incidence in the renal transplant recipient (RTR) population in the near future, robot-assisted radical prostatectomy (RARP) in these patients has been poorly detailed. It is not well understood whether results are comparable to RARP in the non-RTR setting. OBJECTIVE: To describe the surgical technique for RARP in RTR and report results from our multi-institutional experience. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective review of the experience of four referral centers. SURGICAL PROCEDURE: Transperitoneal RARP with pelvic lymph node dissection in selected patients. MEASUREMENTS: We measured patient, PCa, and graft baseline features; intraoperative and postoperative parameters; complications, (Clavien classification); and oncological and functional outcomes. RESULTS AND LIMITATIONS: We included 41 men. The median age, American Society of Anesthesiologists score, preoperative renal function, and prostate-specific antigen were 60 yr (interquartile range [IQR] 57-64), 2 points (IQR 2-3), 45 ml/min (IQR 30-62), and 6.5 ng/ml (IQR 5.2-10.2), respectively. Four men (9.8%) had a biopsy Gleason score >7. The majority of the patients (70.7%) did not undergo lymphadenectomy. The median operating time, hospital stay, and catheterization time were 201 min (IQR 170-250), 4 d (IQR 2-6), and 10 d (IQR 7-13), respectively. At final pathology, 11 men had extraprostatic extension and seven had positive surgical margins. At median follow-up of 42 mo (IQR 24-65), four men had biochemical recurrence, including one case of local PCa persistence and one local recurrence. No metastases were recorded while two patients died from non-PCa-related causes. Continence was preserved in 86.1% (p not applicable) and erections in 64.7% (p = 0.0633) of those who were continent/potent before the procedure. Renal function remained unchanged (p = 0.08). No intraoperative complications and one major (Clavien 3a) complication were recorded. CONCLUSIONS: RARP in RTR is safe and feasible. Overall, operative, oncological, and functional outcomes are comparable to those described for the non-RTR setting, with graft injury remaining undescribed. Further research is needed to confirm our findings. PATIENT SUMMARY: Robot-assisted removal of the prostate is safe and feasible in patients who have a kidney transplant. Cancer control, urinary and sexual function results, and surgical complications seem to be similar to those for patients without a transplant, but further research is needed.
引用
- Marra G, Agnello M, Giordano A, et al. Robotic Radical Prostatectomy for Prostate Cancer in Renal Transplant Recipients: Results from a Multicenter Series. Eur Urol. 2022. PMID: 35750583. doi:10.1016/j.eururo.2022.05.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。